scholarly journals Dorzolamide Chlorhydrate versus Acetazolamide in the Management of Chronic Macular Edema in Patients with Retinitis Pigmentosa: Description of Three Case Reports

2014 ◽  
Vol 6 ◽  
pp. OED.S13617 ◽  
Author(s):  
Elena Pacella ◽  
Loredana Arrico ◽  
Valentina Santamaria ◽  
Paolo Turchetti ◽  
Maria Rosaria Carbotti ◽  
...  
Keyword(s):  
Retinitis Pigmentosa ◽  
Macular Edema ◽  
Systemic Treatment ◽  
Case Reports ◽  
Fundus Photography ◽  
Secondary Effects ◽  
Corrected Visual Acuity ◽  
Therapeutic Protocol ◽  
Topical Dorzolamide ◽  
Remarkable Reduction

Aims To assess the efficacy of topical dorzolamide for treating cystoid macular edema in patients with retinitis pigmentosa and minimize the secondary effects of maintenance therapy in patients with retinitis pigmentosa (RP) who present with chronic microcystic macular edema. Methods To replace acetazolamide systemic treatment, with a topical treatment using 2% dorzolamide in three patients. The methods performed were OCT scan with a Spectralis HRA-OCT, for the measurement of macular thickness and morphology; best corrected visual acuity was assessed using Early Treatment Diabetic Retinopathy Study (ETDRS), was assessed slit-lamp biomicroscopy, ocular tonometry, fundus biomiocrosopy, and color fundus photography. This therapeutic protocol has been applied and described in three patients. Results In all three tested patients, following the administration of dorzolamide in eye drop, we observed a remarkable decrease in macular edema, almost comparable to that obtained with acetazolamide per os. Conclusion The study confirms the anti-edematogenic effect of topical dorzolamide in RP with recurring macular cysts, as this can have a favorable response with topical dorzolamide. In all the three examined patients, the instillation of topical dorzolamide caused a remarkable reduction in their macular edema, as highlighted on OCT.

Recurrence Rate of Cystoid Macular Edema with Topical Dorzolamide Treatment and Its Risk Factors in Retinitis Pigmentosa

Retina ◽  
2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Shotaro Shimokawa ◽  
Yusuke Murakami ◽  
Kohta Fujiwara ◽  
Jun Funatsu ◽  
Shunji Nakatake ◽  
...  
Keyword(s):  
Risk Factors ◽  
Retinitis Pigmentosa ◽  
Macular Edema ◽  
Recurrence Rate ◽  
Cystoid Macular Edema ◽  
Topical Dorzolamide

scholarly journals Intravitreal and Subtenon Depot Triamcinolone as Treatment of Retinitis Pigmentosa Associated Cystoid Macular Edema

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Sidnei Barge ◽  
Renata Rothwell ◽  
Paula Sepúlveda ◽  
Luís Agrelos
Keyword(s):  
Visual Acuity ◽  
Retinitis Pigmentosa ◽  
Macular Edema ◽  
Intravitreal Injection ◽  
Cystoid Macular Edema ◽  
Treatment Options ◽  
Corrected Visual Acuity ◽  
Anatomic Results ◽  
The Right ◽  
Decrease In Visual Acuity

We present a case of retinitis pigmentosa (RP) related cystoid macular edema (CME) refractory to oral acetazolamide and topical ketorolac that was treated with intravitreal and subtenon depot triamcinolone. A 32-year-old male with RP presented with complaints of bilateral decrease in visual acuity. His best-corrected visual acuity (BCVA) was 20/50 in the right eye and 20/100 in the left eye. After being informed of the available treatment options, the patient received bilateral intravitreal injection triamcinolone. The patient’s BCVA improved to 20/40 in the right eye and 20/50 in the left eye and the CME was resorbed. However, 5 months after the injection in the left eye and two months in the right eye, visual acuity decreased due to recurrence of CME. We performed a second intravitreal injection in the left eye with improvement of visual and anatomic results, but we observed a recurrence of CME. Afterwards, we treated the patient with subtenon depot triamcinolone in both eyes, with the result that there was no recurrence after 4 months in OD or after 3 months in OS. We conclude that intravitreal and subtenon depot triamcinolone appear to provide at least temporary benefit in refractory CME as regards the improvement of visual acuity.

scholarly journals Regression of taxane-related cystoid macular edema after topical dorzolamide treatment: two case reports

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Mitsuru Otsubo ◽  
Reiko Kinouchi ◽  
Takayuki Kamiya ◽  
Akitoshi Yoshida
Keyword(s):  
Visual Acuity ◽  
Side Effects ◽  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Corrected Visual Acuity ◽  
Old Japanese ◽  
Multiple Metastases ◽  
Topical Dorzolamide ◽  
The Right ◽  
Best Corrected Visual Acuity

Abstract Background Cystoid macular edema is a rare, vision-threatening side effect of the taxane family of anticancer agents. There is no established treatment or standard treatment protocol for taxane-related cystoid macular edema. Here, we report two cases of taxane-related cystoid macular edema that were treated with topical dorzolamide. Case presentation In case 1, a 72-year-old Japanese woman with bilateral geographic choroiditis reported for a follow-up visit with a complaint of blurred vision in both eyes for 2 months after starting nanoparticle albumin-bound paclitaxel chemotherapy for multiple metastases of her breast cancer. Her best-corrected visual acuity had dropped from 1.2 to 0.9 in the right eye and from 1.0 to 0.4 in the left eye. Fundus examination showed no newly active geographic choroiditis lesion, but optical coherence tomography exhibited cystoid macular edema. We suspected taxane-related cystoid macular edema and terminated nanoparticle albumin-bound paclitaxel, and started topical dorzolamide treatment. Cystoid macular edema nearly resolved within 6 weeks in the right eye and within 10 weeks in the left eye after starting topical dorzolamide treatment. The resolution of cystoid macular edema without leaving a chorioretinal scar after discontinuation of paclitaxel confirmed our initial diagnosis of taxane-related cystoid macular edema. A few inconspicuous cystoid spaces persisted at the parafovea for a year after dorzolamide treatment ended, but regressed after restarting dorzolamide treatment without any side effects. Best-corrected visual acuity improved to 1.2 in the right eye and 1.0 in the left eye. In case 2, a 70-year-old Japanese man, who received nanoparticle albumin-bound paclitaxel for pancreatic cancer with multiple metastases, developed bilateral cystoid macular edema. Best-corrected visual acuity was 0.3 bilaterally. Cystoid macular edema resolved within 5 weeks after stopping nanoparticle albumin-bound paclitaxel and starting topical dorzolamide treatment confirming the diagnosis of taxane-related cystoid macular edema. Nine weeks later, best-corrected visual acuity improved to 0.8 in the right eye and 1.0 in the left eye. Conclusions Cystoid macular edema in each case resolved within a few months without any side effects using topical dorzolamide and terminating taxane-based chemotherapy. Topical dorzolamide appears to be a safe and effective treatment option for patients with taxane-related cystoid macular edema whose quality of life is threatened by visual disturbances.

Effect of Topical Dorzolamide on Cystoid Macular Edema in Retinitis Pigmentosa

2020 ◽  
Vol 4 (10) ◽  
pp. 1036-1039
Author(s):  
Shotaro Shimokawa ◽  
Kohta Fujiwara ◽  
Yusuke Murakami ◽  
Jun Funatsu ◽  
Shunji Nakatake ◽  
...  
Keyword(s):  
Retinitis Pigmentosa ◽  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Topical Dorzolamide

The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa

2012 ◽  
Vol 250 (6) ◽  
pp. 809-814 ◽  
Author(s):  
Yasuhiro Ikeda ◽  
Toshio Hisatomi ◽  
Noriko Yoshida ◽  
Shoji Notomi ◽  
Yusuke Murakami ◽  
...  
Keyword(s):  
Retinitis Pigmentosa ◽  
Macular Edema ◽  
Clinical Efficacy ◽  
Cystoid Macular Edema ◽  
Topical Dorzolamide

Comparison of Topical Dorzolamide and Ketorolac Treatment for Cystoid Macular Edema in Retinitis Pigmentosa and Usher's Syndrome

2014 ◽  
Vol 233 (1) ◽  
pp. 43-50 ◽  
Author(s):  
Ricardo Filipe Lemos Reis ◽  
Nuno Moreira-Gonçalves ◽  
Sérgio E. Estrela Silva ◽  
Elisete M. Brandão ◽  
Fernando M. Falcão-Reis
Keyword(s):  
Visual Acuity ◽  
Retinitis Pigmentosa ◽  
Macular Edema ◽  
Daily Regimen ◽  
Foveal Thickness ◽  
Treatment Groups ◽  
Dorzolamide Hydrochloride ◽  
Topical Dorzolamide ◽  
Usher’S Syndrome

Purpose: To investigate the topical effect of dorzolamide versus ketorolac on retinitis pigmentosa (RP) and Usher's syndrome (US) macular edema. Methods: Prospective, randomized and interventional study. A total of 28 eyes of 18 patients were included. Five eyes had US, 23 had RP. Fifteen eyes were allocated to ketorolac tromethamine 0.5% (4 drops daily regimen) and 13 eyes to dorzolamide hydrochloride 2% (3 drops daily regimen) treatment groups. Snellen's best-corrected visual acuity (BCVA), foveal thickness (FT) and foveal zone thickness (FZT) measured by Stratus® optical coherence tomography (OCT) were evaluated at baseline, 1, 3, 6 and 12 months after treatment. Results: Patients assigned to ketorolac had a baseline BCVA of 0.37 ± 0.17 logMAR which improved at the end of 1 year to 0.28 ± 0.16 (p = 0.02). Three eyes (20%) of 2 patients improved by 7 letters or more. Mean FT and FZT did not change significantly during the study follow-up. After 1 year of treatment, 4 eyes (27%) of 3 patients showed an improvement of at least 16% of FT and 11% of FZT. Patients assigned to dorzolamide had a baseline BCVA of 0.48 ± 0.34 logMAR which improved in the first 6 months (0.40 ± 0.30; p = 0.01), with a decrease at 1 year (0.42 ± 0.27; p = 0.20). Seven eyes (54%) of 5 patients had an improvement of 7 letters or more. Mean FT and FZT did not change significantly either. After 1 year of treatment, 3 eyes (23%) of 2 patients showed an improvement of at least 16% on FT and 11% on FZT. Conclusions: Results suggest that dorzolamide and ketorolac might improve visual acuity and therefore be of interest in selected cases. No relationship between retinal thickness fluctuation and visual acuity was found. Sample size was a limitation to the study.

scholarly journals Efficacy of topical dorzolamide 2% in diabetic cystoid macular edema

2021 ◽  
Vol 14 (9) ◽  
pp. 1413-1418
Author(s):  
Amani E Badawi ◽  
◽  
Eman M Elhefney ◽  
Sherein M. Hagras ◽  
Ameera G Abdelhameed ◽  
...  
Keyword(s):  
Macular Edema ◽  
Cystoid Macular Edema ◽  
Open Study ◽  
Post Treatment ◽  
Macular Thickness ◽  
Treatment Results ◽  
Corrected Visual Acuity ◽  
Systemic Side Effects ◽  
The Mean ◽  
Topical Dorzolamide

AIM: To study the effect of topical dorzolamide 2% on macular thickness reduction in diabetic cystoid macular edema (CME). METHODS: This was a prospective, non-randomized, open study including eyes with diabetic macular edema (DME). All eyes received topical dorzolamide 2% three times daily for one month. Changes in best-corrected visual acuity (BCVA), and central macular thickness (CMT) by optical coherence tomography) were evaluated at 1wk, 1, and 3mo post-treatment. RESULTS: Ninety-three eyes (84 patients) were included. Mean±SD (logMAR) BCVA improved significantly from 1.08±0.26 pretreatment to 0.66±0.24 at 1mo and 0.87±0.26 at 3mo post-treatment (P<0.001 both). The mean±SD CMT was significantly reduced from 535.27±97.4 μm at baseline to 357.43±125.8 μm at 1mo and 376.23±114.5 μm at 3mo post-treatment (P<0.001 both). No significant ocular or systemic side effects were recorded. CONCLUSION: Topical dorzolamide 2% results in significant improvement of mean BCVA and reduction of mean CMT at 3mo post-treatment. It can be used as an effective, affordable, and safe therapy for treatment of non-refractory diabetic CME.

Sign in / Sign up

Export Citation Format

Share Document